Indigenous vaccine COVAXIN demonstrates 100 per cent efficacy against severe COVID-19 disease in Phase-3 interim analysis; Shows overall efficacy of 78 per cent

Apr 21, 2021
8:04PM

Indigenous vaccine COVAXIN demonstrates 100 per cent efficacy against severe COVID-19 disease in Phase-3 interim analysis; Shows overall efficacy of 78 per cent

@BharatBiotech
Bharat Biotech and ICMR today announced interim results from Phase - 3 trials of COVAXIN. It has reported overall interim clinical efficacy of 78 per cent of Covaxin. It said that the efficacy of the vaccine against severe COVID-19 disease was 100 per cent. 

In a statement, the company said, the second interim results showed India’s First COVID-19 Vaccine had demonstrated strong primary efficacy against severe COVID-19 disease. It said, due to the recent surge in cases, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78 per cent against mild, moderate, and severe COVID-19 disease.
 

Popular posts from this blog

Health Ministry launches informational video series ‘COVID GuruKool’ on social media platforms

Massive rescue and search operation continues in Chamoli district, Uttarakhand

Pradhan Mantri Fasal Bima Yojana completes 5 years; govt urges farming community to take advantage of scheme